Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Asthma

ClinicalTrials.gov lists 4,534 trials for Asthma or a narrower condition beneath it. AstraZeneca has the most among industry and government lead sponsors, with 314.

MeSH D001249 Respiratory Tract Diseases C08 C20
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 375 Phase 1/2 Phase 1/2 50 Phase 2 Phase 2 579 Phase 2/3 Phase 2/3 49 Phase 3 Phase 3 565 Phase 4 Phase 4 442 Not applicable Not applicable 1,204 Observational Observational 1,269 Phase 1 Phase 1 375 Phase 1/2 Phase 1/2 50 Phase 2 Phase 2 579 Phase 2/3 Phase 2/3 49 Phase 3 Phase 3 565 Phase 4 Phase 4 442 Not applicable Not applicable 1,204 Observational Observational 1,269

Trials per phase (log scale)

1 more section with rows

4,453 of the 4,534 trials are tagged with Asthma itself; the rest are tagged with a narrower condition beneath it.

Get the Asthma report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Asthma trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 6 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 236

1990: 9 trials (Observational 7, Not applicable 1, Phase 3 1) 1991: 5 trials (Observational 4, Phase 3 1) 1992: 7 trials (Observational 5, Not applicable 1, Phase 4 1) 1993: 5 trials (Observational 3, Phase 4 1, Phase 3 1) 1994: 6 trials (Observational 4, Not applicable 1, Phase 3 1) 1995: 6 trials (Observational 5, Phase 3 1) 1996: 10 trials (Observational 5, Not applicable 3, Phase 4 1, Phase 2 1) 1997: 10 trials (Observational 5, Phase 4 1, Phase 3 3, Phase 2 1) 1998: 17 trials (Observational 4, Not applicable 3, Phase 4 4, Phase 3 5, Phase 2 1) 1999: 30 trials (Observational 16, Not applicable 5, Phase 4 2, Phase 3 3, Phase 2/3 1, Phase 2 3) 2000: 30 trials (Observational 14, Not applicable 4, Phase 4 4, Phase 3 6, Phase 2/3 1, Phase 1/2 1) 2001: 37 trials (Observational 11, Not applicable 12, Phase 4 3, Phase 3 6, Phase 2 4, Phase 1 1) 2002: 68 trials (Observational 7, Not applicable 12, Phase 4 11, Phase 3 26, Phase 2 10, Phase 1/2 1, Phase 1 1) 2003: 93 trials (Observational 10, Not applicable 25, Phase 4 21, Phase 3 30, Phase 2 7) 2004: 109 trials (Observational 21, Not applicable 22, Phase 4 19, Phase 3 32, Phase 2/3 2, Phase 2 10, Phase 1 3) 2005: 148 trials (Observational 31, Not applicable 24, Phase 4 25, Phase 3 33, Phase 2/3 4, Phase 2 19, Phase 1/2 1, Phase 1 11) 2006: 173 trials (Observational 27, Not applicable 36, Phase 4 33, Phase 3 29, Phase 2/3 7, Phase 2 25, Phase 1/2 4, Phase 1 12) 2007: 209 trials (Observational 61, Not applicable 33, Phase 4 38, Phase 3 30, Phase 2 30, Phase 1/2 2, Phase 1 15) 2008: 192 trials (Observational 43, Not applicable 40, Phase 4 16, Phase 3 21, Phase 2/3 1, Phase 2 41, Phase 1/2 5, Phase 1 25) 2009: 213 trials (Observational 60, Not applicable 48, Phase 4 23, Phase 3 14, Phase 2/3 4, Phase 2 43, Phase 1/2 4, Phase 1 17) 2010: 217 trials (Observational 44, Not applicable 39, Phase 4 19, Phase 3 24, Phase 2/3 6, Phase 2 51, Phase 1/2 4, Phase 1 30) 2011: 210 trials (Observational 59, Not applicable 47, Phase 4 19, Phase 3 28, Phase 2/3 2, Phase 2 32, Phase 1/2 2, Phase 1 21) 2012: 236 trials (Observational 49, Not applicable 65, Phase 4 15, Phase 3 26, Phase 2/3 3, Phase 2 53, Phase 1/2 3, Phase 1 22) 2013: 163 trials (Observational 34, Not applicable 40, Phase 4 17, Phase 3 19, Phase 2/3 2, Phase 2 28, Phase 1/2 2, Phase 1 21) 2014: 163 trials (Observational 29, Not applicable 51, Phase 4 15, Phase 3 26, Phase 2/3 2, Phase 2 19, Phase 1/2 2, Phase 1 19) 2015: 204 trials (Observational 52, Not applicable 67, Phase 4 13, Phase 3 27, Phase 2/3 3, Phase 2 26, Phase 1/2 1, Phase 1 15) 2016: 184 trials (Observational 46, Not applicable 66, Phase 4 18, Phase 3 16, Phase 2 14, Phase 1/2 2, Phase 1 22) 2017: 204 trials (Observational 61, Not applicable 61, Phase 4 13, Phase 3 22, Phase 2/3 3, Phase 2 23, Phase 1/2 2, Phase 1 19) 2018: 166 trials (Observational 51, Not applicable 49, Phase 4 17, Phase 3 23, Phase 2 15, Phase 1/2 1, Phase 1 10) 2019: 185 trials (Observational 59, Not applicable 59, Phase 4 12, Phase 3 19, Phase 2 14, Phase 1/2 2, Phase 1 20) 2020: 140 trials (Observational 63, Not applicable 38, Phase 4 11, Phase 3 8, Phase 2/3 2, Phase 2 8, Phase 1/2 1, Phase 1 9) 2021: 193 trials (Observational 81, Not applicable 45, Phase 4 18, Phase 3 11, Phase 2/3 2, Phase 2 12, Phase 1/2 2, Phase 1 22) 2022: 173 trials (Observational 61, Not applicable 54, Phase 4 9, Phase 3 15, Phase 2/3 1, Phase 2 17, Phase 1/2 3, Phase 1 13) 2023: 180 trials (Observational 62, Not applicable 65, Phase 4 7, Phase 3 17, Phase 2/3 1, Phase 2 16, Phase 1/2 2, Phase 1 10) 2024: 202 trials (Observational 72, Not applicable 70, Phase 4 18, Phase 3 16, Phase 2/3 1, Phase 2 11, Phase 1 14) 2025: 155 trials (Observational 54, Not applicable 49, Phase 4 7, Phase 3 9, Phase 2/3 1, Phase 2 21, Phase 1/2 2, Phase 1 12)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 141
2025 155
2024 202
2023 180
2022 173
2021 193
2020 140
2019 185
2018 166
2017 204

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 160 trials starting in 2026 and about 160 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 35 months from start to primary completion across 212 trials still running at the 2026-10-09 snapshot; registered median of 18 months across 3,191 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Asthma trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 375
Phase 1/2 50
Phase 2 579
Phase 2/3 49
Phase 3 565
Phase 4 442
Not applicable 1,204
Observational 1,269
Expanded access 1

How many Asthma trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 105
Recruiting 295
Enrolling by invitation 23
Active, not recruiting 101
Completed 3,118

Showing 5 of 10 statuses.

Start your 14-day trial Email me all 10 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Asthma trials? (11)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
AstraZeneca 314
GlaxoSmithKline 262
National Heart, Lung, and Blood Institute (NHLBI) 76
Novartis Pharmaceuticals 73
Organon and Co 66

Showing 5 of 11 sponsors.

Start your 14-day trial Email me all 11 sponsors as a PDF

Which drugs are being tested for Asthma? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Montelukast 111
OPN-375 92
Albuterol 56
Formoterol 32

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Budesonide EC 66
Drug: Omalizumab 66
Mepolizumab SC 47
Benralizumab Arm B 43
Formoterol-budesonide 42

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Asthma trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Invasive cancer of any type 4,851 1
Asthma 2,990 237
Major cardiovascular event 2,415 1
Gastrointestinal bleeding 2,232 1
Hypercalcemia 870 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Asthma? (5,964)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Effect of tezepelumab on asthma exacerbations co-occurring with infection-attributed acute respiratory illnesses. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2026 Yes
Albuterol-budesonide rescue inhaler for asthma: Patterns of use and safety in the MANDALA trial. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2026 Yes
Allergic sensitization in asthma and COPD in the NOVELTY study. Respiratory medicine 2026 Yes
Outcomes after biologic initiation among patients with severe asthma and normal lung function in the CHRONICLE study. Respiratory research 2026 Yes
Mitigating chronic respiratory disease through the lens of multimorbidity: the MARES mixed-methods study protocol. BMJ open 2026 Yes

Showing 5 of 5,964 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (6)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages